after stratification for extent of small cell lung cancer , 109 patients were randomized to receive cycles of chemotherapy with cyclophosphamide , doxorubicin , and vp-16-213 [ cavp16 ( regimen i ) ] or to receive cavp16 to maximum response ( minimum of three courses ) and then chemotherapy with ccnu , methotrexate , vincristine , and procarbazine ( comp ) alternating with cavp16 ( regimen ii ) .
C0010583
cyclophosphamide
C0056167
comp